Lupin has informed that it enclosed a Press release regarding receipt of US FDA approval for the Company’s Abbreviated New Drug Application for Pitavastatin Tablets, 1 mg, 2 mg, and 4 mg, to market a generic equivalent of Livalo Tablets, 1 mg, 2 mg, and 4 mg, of Kowa Company.
The above information is a part of company’s filings submitted to BSE.